Login to Your Account

Word on the Street

Monday, November 7, 2011

"At the end of the day, the fundamentals of a company are what matters to investors."

Alan Auerbach, CEO of Puma Biotechnology Inc., arguing that it doesn't matter whether a firm goes public via IPO or reverse merger

"We don't want everyone going public. That's bad for business."

Matthew Perry, of Biotechnology Value Fund, explaining that good companies can always IPO, but an "IPO window" means bad companies are getting out

"I think you still need the mad scientist type CSO. You can't rent that person out."

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription